Radiopharmaceuticals and Radiochemicals
for research and clinical use
We are a leading provider of PET-radiopharmaceuticals and radionuclides for the nuclear medicine community. The nuclear medicine community in the Benelux region and beyond successfully uses our GMP-compliant radiopharmaceuticals and radionuclides in all stages of clinical care: from pre-clinical research to clinical studies and commercial usage.
Founded in 1987, BV Cyclotron VU rapidly developed into a well-established producer of radiopharmaceuticals and radionuclides for imaging techniques, such as PET and SPECT. Equipped with three cyclotrons and several clean room facilities, we are at the forefront of the nuclear medicine community, with location on the campus of the VU University Amsterdam.
We currently employ about 30 people. Our portfolio offers seven products, with a production output of 35,000 patient doses per year:
- Iodine-124 [124I
] - Zirconium-89 [89Zr ]
- Fludeoxyglucose [18FFDG ]
- 81Rb/81mKr Generator
- Type A Transport Container
- Sodium Iodide [124I for Injection ]
*Other 18F-tracers: – Fluoromethycholine – Florbetaben – Sodium Fluoride [18F
]News and articles that we find of particular interest:
Study validates the use of Cerenkov Luminescence Imaging for evaluation of 89Zr-rituximab in NHL using Humanized Transgenic Mouse Model
8/4/2013: With the purpose of studying the application of Cerenkov Luminescence Imaging (CLI) for non-Hodgkin's lymphoma (NHL) using PET, researchers from the Molecular Imaging Program at Stanford (MIPS) employed 89Zr-labeled mAb rituximab as tracer, in a humanized transgenic mouse model expressing human CD20 (huCD20). The results could establish a correlation between CLI and PET.
89Zr-labeled panitumumab reveals potential for immuno-PET of HER-1 expressing carcinomas
8/4/2013: Researchers from the Frederick National Laboratory for Cancer Research have recently published the results of a study to evaluate the potential of imaging, in humans, using the mAb panitumumab, labeled with 89Zr and bound to desferrioxamine (DFO).
Pilot study to test the clinical feasibility of PET/CT lymphoscintigraphy with 89Zr-nanocolloidal albumin for identification of sentinel nodes has positive results
6/2/2013: In a continuing effort to improve the fine techniques used for precise detection of ever smaller and more hidden tumors, researchers from the Department of Otolaryngology/Head and Neck Surgery of the VU University Medical Center (Amsterdam, The Netherlands) have recently published the outline of their latest endeavor.
Announcement: PerkinElmer to become Cyclotron’s new sales, marketing and distribution partner for 89Zr and 124I
6/2/2013: As of March 1, 2013, PerkinElmer will become Cyclotron's sales, marketing and distribution partner for the long-lived PET isotopes 89Zr and 124I.
New review article covers the past and the future of PET imaging with 89Zr, from radiochemistry to clinical application
6/2/2013: Recent review on the use of 89Zr in PET imaging provides researchers from all levels with a critical overview of what has been or could still be achieved in this fast-developing field.
Treatment with lapatinib and and an antibiotic shown to reduce the expression of HER2, and consequent uptake of (89)Zr-trastuzumab-F(ab’)(2), in SKBR3 xenografts
29/1/2013: An investigation in the context of improving therapies directed at the human epidermal growth factor receptor 2 (HER2) has been recently carried out by Oude Munnink and colleagues at the Department of Medical Oncology from the University of Groningen, the Netherlands.